# **SUPPLEMENTARY TABLE 2** Frequency of androgen receptor (AR) copy number variation stratified by systemic therapy at time of circulating cell-free DNA (cfDNA) collection

|  |  |  |
| --- | --- | --- |
|  | **Systemic therapy at time of cfDNA collection** |  |
| **Copy number variation** | **Abiraterone (*n* = 29)** | **Enzalutamide (*n* = 19)** | **Other (*n* = 14)** |  ***P* (Χ2)** |
| **AR amplification, *n* (%)** | 5 (17) | 10 (53) | 3 (21) | **0.02** |
| **AR gain or amplification, *n* (%)** | 10 (34) | 13 (68) | 5 (36) | 0.05 |

# NB: GISTIC peak at AR was more significant in the enzalutamide cohort than the abiraterone cohort (Q-bound significance = 0.002 vs. 0.038; G-score =6.657 vs. 4.125 respectively).